PMID- 19460063
OWN - NLM
STAT- MEDLINE
DCOM- 20110118
LR  - 20181201
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 40
IP  - 3
DP  - 2010 Mar
TI  - Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory 
      metastatic prostate cancer: double tubulin targeting.
PG  - 201-8
LID - 10.1111/j.1445-5994.2009.01987.x [doi]
AB  - BACKGROUND: Androgen ablation is the standard treatment for advanced prostate 
      cancer. However, most patients will eventually develop progressive 
      hormone-refractory prostate cancer (HRPC). The aim of the Pacl-Vin study was to 
      determine the efficacy and safety of paclitaxel in combination with vinorelbine 
      in patients with HRPC, following from a phase I trial. METHODS: Thirty castrate 
      patients with progressive, metastatic prostate cancer were enrolled. Patients 
      were treated with paclitaxel 40 mg/m2, vinorelbine 20 mg/m2 intravenously on day 
      1 and day 8 of a 21-day cycle. RESULTS: Two patients demonstrated a partial 
      response and seven patients had stable disease from a cohort of 10 patients with 
      measurable disease. Of 30 patients assessable for prostate-specific antigen (PSA) 
      response, 19 showed stable disease, which was maintained for at least 4 weeks, 
      while six (20%) experienced>or=50% decline in PSA levels. Median overall survival 
      was 7.3 months (interquartile range (IQR): 4.7-9.9 months). Median 
      progression-free survival was 3.3 months (IQR: 2.5-7.0 months). Improvement in 
      quality of life measures was noted after three cycles of therapy. Grade 3 and 4 
      toxicities were: neutropenia 8%, febrile neutropenia 4%, infection 2%, anaemia 
      3%, lethargy 1% and somnolescence 1%. One patient died as a result of neutropenic 
      sepsis. CONCLUSION: In a poor prognostic cohort of patients paclitaxel and 
      vinorelbine is a tolerable regimen, with a 20% PSA and objective response rate. 
      The majority of patients achieved PSA stability. Furthermore, quality of life 
      parameters, such as pain, were improved. However, the low level of activity of 
      this regimen precludes its further testing.
FAU - Sewak, S
AU  - Sewak S
AD  - The Andrew Love Cancer Centre, The Geelong Hospital, Victoria, Australia. 
      sewaks01@yahoo.com
FAU - Kosmider, S
AU  - Kosmider S
FAU - Ganju, V
AU  - Ganju V
FAU - Woollett, A
AU  - Woollett A
FAU - Yeow, E G
AU  - Yeow EG
FAU - Le, B
AU  - Le B
FAU - Henry, M
AU  - Henry M
FAU - Debrincat, M A
AU  - Debrincat MA
FAU - Bell, R
AU  - Bell R
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20090521
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - 0 (Tubulin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
CIN - Intern Med J. 2010 Dec;40(12):864-5. PMID: 21199229
MH  - Adenocarcinoma/drug therapy/pathology/secondary
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Drug Administration Schedule
MH  - Drug Delivery Systems/*methods
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Paclitaxel/*administration & dosage
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/blood/*drug therapy/*pathology
MH  - Tubulin/*blood
MH  - Vinblastine/administration & dosage/*analogs & derivatives
MH  - Vinorelbine
EDAT- 2009/05/23 09:00
MHDA- 2011/01/19 06:00
CRDT- 2009/05/23 09:00
PHST- 2009/05/23 09:00 [entrez]
PHST- 2009/05/23 09:00 [pubmed]
PHST- 2011/01/19 06:00 [medline]
AID - IMJ1987 [pii]
AID - 10.1111/j.1445-5994.2009.01987.x [doi]
PST - ppublish
SO  - Intern Med J. 2010 Mar;40(3):201-8. doi: 10.1111/j.1445-5994.2009.01987.x. Epub 
      2009 May 21.